In summary, the current study highlights for the first time that the presence of CHD1L over-expression in breast cancer patients, as measured by immunohistochemical analyses, is more likely to be associated with aggressive tumor biology rather than large tumor burden in breast cancer. The gene discussed is CHD1L; the disease is breast cancer.